Amyloid-β, tau pathology, and biomarkers of neurodegeneration make up the core
diagnostic biomarkers of Alzheimer disease (AD). However, these proteins represent only a …

Background Altered proteome profiles have been reported in both postmortem brain tissues
and body fluids of subjects with Alzheimer disease (AD), but their broad relationships with …

Alzheimer's disease (AD) is the most common form of dementia, with cerebrospinal fluid
(CSF) β-amyloid (Aβ), total Tau, and phosphorylated Tau providing the most sensitive and …

Alzheimer's disease (AD) is a neurodegenerative disease with heterogenous
pathophysiological changes that develop years before the onset of clinical symptoms. These …

Alzheimer's disease (AD) features a complex web of pathological processes beyond
amyloid accumulation and tau-mediated neuronal death. To meaningfully advance AD …

Background Identification of the physiologic changes that occur during the early stages of
Alzheimer's disease (AD) may provide critical insights for the diagnosis, prognosis, and …

Background Clinicopathological studies suggest that Alzheimer's disease (AD) pathology
begins∼ 10–15 years before the resulting cognitive impairment draws medical attention …

Background. According to recent studies, amyloid‐β (Aβ) isoforms as cerebrospinal fluid
(CSF) biomarkers have remarkable predictive value for cognitive decline in the early stages …

Introduction Alzheimer's disease (AD) is the most common cause of dementia, characterized
by progressive cognitive decline. Protein biomarkers of AD brain pathology, including β …

Introduction Blood proteins are emerging as candidate biomarkers for Alzheimer's disease
(AD). We systematically profiled the plasma proteome to identify novel AD blood biomarkers …